Emergency. 2018; 6 (1): e44 CA S E RE P O RT Hyper Acute Quadriplegia with Chronic Lead Toxicity; a Case Report Mehdi Mesri1, Fares Najari2∗, Ideh Baradaran Kayal3, Dorsa Najari4 1. Quran and Hadith Research Center Life Style Institute, Baqiyatallah University of Medicaid Sciences, Tehran, Iran. 2. Toxicologist and Forensic Medicine Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Legal Medicine Organization of Alborz, Karaj, Iran. 4. Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Received: May 2018; Accepted: July 2018; Published online: 15 July 2018 Abstract: Industrial lead toxicity is more common among miners. This type of toxicity occurs in two forms: acute and chronic. Chronic toxicity is associated with different levels of brain dysfunction, motor impairment, cognitive dysfunction, and neuropsychiatric problems, including depression, anxiety, irritability, and emotional disorders. However, quadriplegia induced by chronic toxicity is very rare. Here we report a 37-year-old male patient with a history of desert hunting, where he used to roll lead bullets in his mouth, who was admitted with sensory impairment, muscle weakness, and quadriplegia and final diagnosis of lead toxicity. Keywords: Lead poisoning, nervous system, adult; quadriplegia; emergency service, hospital; case report © Copyright (2018) Shahid Beheshti University of Medical Sciences Cite this article as: Mesri M, Najari F, Baradaran Kayal I, Najari D. Hyper Acute Quadriplegia with Chronic Lead Toxicity; a Case Report . 2018; 6 (1): e44. 1. Introduction Industrial lead poisoning is one of the oldest types of occupa- tional poisoning, which dates back to at least 5000 years ago. Nonorganic lead can be found in workers of ceramic glaze, food canning, color, and cosmetic companies. There is also nonorganic lead in drinking water, industrial dust, and motor vehicle exhaust. Lead levels are higher among adult workers who are in contact with industrial lead. This type of lead is mainly absorbed through the lungs and gastrointestinal tract (1, 2). Neurotoxicity occurs due to physiological and neurological changes, which are caused by exposure to toxic agents. It may cause changes in cognition, memory, and mood or result in the development of psychiatric disorders (3). Neurotoxicity induced by heavy metals, including lead, mercury, and ar- senic, has been explored more. This type of toxicity has two common forms: acute and chronic. Symptoms of acute poi- ∗Corresponding Author: Fares Najari; Department of Forensic Medicine, Shahid Beheshti University of Medical Sciences, Daneshjou Boulevard, Arabi Ave, Velenjak, Tehran, Iran. P.O.Box: 1983969411. Email: na- jari.hospital@sbmu.ac.ir Tel: 00989123195140 soning include nausea, headache, cognitive problems, and emotional disorders. Chronic exposure often occurs in industrial workplaces. In chronic exposure, symptoms are mostly neurological and psychiatric, including depression, anxiety, and irritability. Chronic exposure to lead may cause symptoms, such as fa- tigue, brain dysfunction, motor impairment, and cognitive dysfunction in general (4). Studies show that reduction of sensory responses and cognitive impairment occur in male workers with blood lead levels ≥ 40 µg/100ml (5). Peripheral motor neuropathy and reduced velocity of peripheral nerve conduction have been also reported in some cases of chronic lead toxicity (6, 7). At high doses, lead toxicity causes irritability, headache, men- tal fatigue, reduced concentration, memory loss, tremor, and hallucinations. It may even result in quadriplegia, seizure, delirium, coma, or death. In the event of lead toxicity, early diagnosis, careful evaluation, and immediate treatment are very important (8). Therefore, it is necessary to be familiar with the rare symptoms of chronic lead toxicity. This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: www.jemerg.com M. Mesri et al. 2 2. Case Presentation The patient was a 37-year-old married man, who was a hunter of wild desert animals and used to roll lead bullets in his mouth. In the spring of 2015, he was referred to the hospital with abdominal pain and tenderness which had ini- tiated almost 30 days before his admission. The patient was admitted to the surgical gastroenterology department due to abdominal pain and tenderness, weight loss, loss of ap- petite, and diffuse itching. On the tenth day of hospitaliza- tion, the patient suddenly developed sensory impairment, muscle weakness, and quadriplegia. With suspicion to su- per acute toxicity, he was transferred to the poisoning depart- ment. The results of abdominal and pelvic computed tomography (CT) scans were normal, just like the results of endoscopy and colonoscopy. Moreover, the results of Doppler ultra- sound and brain magnetic resonance imaging (MRI) were normal. Electromyography (EMG) and nerve conduction ve- locity (NCV ) suggested axonal neuropathy in all the limbs. The patient’s neurological symptoms, such as motor neu- ropathy, quadriplegia, walking disability, and paresthesia, were exacerbated since the time of admission. Cognitive disorders, including thought disorders, accompanied by dis- tress, anxiety, and delirium, were evident in the patient. Laboratory findings showed increased levels of liver en- zymes (AST: 220 unit/L, ALT;120 unit/L), bilirubin(Total: 3 mg/dl with Direct: 1/2 mg/dl), lactate dehydrogenase (LDH: 750 unit/L), amylases (220 unit/L), leukocytosis (22000/m3), and anemia (Mean Hemoglobin: 8.5 g/dl, MCV: 75). No basophilic stippling was observed in the peripheral blood smear during hospitalization. The patient’s medical history indicated chronic abdominal pain about four years before his referral for which he was hospitalized for several days and was discharged with a good general condition. With suspicion of lead toxicity the serum lead level was measured, which indicated a lead level of 150 µcg/dL. Considering the likelihood of acute lead poi- soning with repeated attacks, chelation therapy was applied according to the standard protocols of the medical toxicol- ogy book. Therapeutic instructions included Livergol tablets, adenosine monophosphate (AMP), bronchoalveolar lavage (BAL), ethylenediaminetetraacetic acid (EDTA), calcium, and sodium. During treatment with BAL, the patient experienced stress disorders, exacerbated delirium, and tachycardia. Methadone was initiated to overcome the suspected drug withdrawal syndrome. However, the symptoms did not re- solve, and sedative medications such as midazolam were used to manage them. After two days of treatment with BAL, which led to restlessness, distress, and tachycardia, BAL treatment was temporarily terminated. After stabilization, BAL was continued in the intensive care unit (ICU). BAL was continued with the same dosage as the patient was hospitalized in the ICU. His general condition gradu- ally improved, and BAL-induced complications (tachycar- dia, hypertension, and distress), which persisted for three to five days, were resolved. Once the lead level reached 120 µcg/dL, treatment was continued with ETDA+BAL with the same dosage. After three days of treatment, the lead level reached 85 µcg/dL. Therefore, BAL was terminated and sub- stituted with oral succimer. After three days of treatment with succimer, the lead level reached 65 µcg/dL. At this lead level, BAL and EDTA admin- istration was terminated, and succimer was continued with the same dosage. During treatment, the ferritin level became normal. After 15 days of treatment, the patient’s anemia was improved and the level of liver enzymes gradually decreased and eventually reached the normal level after three weeks of treatment. After four months of treatment with succimer, the lead level reached 60 µcg/dL; treatment continued with suc- cimer (divided doses every 12 hours). However, neurological symptoms, specifically muscle weakness and neuropathy, re- mained unchanged. With proper physiotherapy, most disor- ders, including muscle weakness of the upper and lower ex- tremities, improved. After one year of follow-up, he was com- pletely alert, without any neurological deficits; his cognition and perception also improved. 3. Discussion Several studies have shown that industrial lead exposure can cause memory impairment and reduce the processing speed, reading comprehension, motor skills, and executive func- tions. Moreover, anxiety, depression, and phobia are prob- able in these patients. In our study, the patient suffered from tremor, paresthesia, peripheral neuropathy, quadriplegia, and walking disability. In a case report by Beig Mohammadi et al., entitled “Quadriplegia induced by lead-contaminated opium”, a patient was examined with quadriplegia. Despite the resolution of all symptoms and reduction of blood lead level, the patient was discharged with quadriplegia (9). In the present report, which is only different from the mentioned study in terms of the contamination source, the patient was completely recovered after the treatment period and one- year follow-up. A study by D. A. Gidlow showed that in industrial workers with lead levels above 40 µg/100ml, neurotoxicity was char- acterized by motor deficiency and cognitive problems and even in some cases by peripheral neuropathy. Memory and concentration problems, besides visual impairment, occur at lead levels higher than 50 µg/100ml (1). A study by Sansar W, which was conducted on mice, found that lead levels of 100 µg/100ml can cause changes in the glial and neuronal systems and result in functional and behavioral impairments This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: www.jemerg.com 3 Emergency. 2018; 6 (1): e44 (10). In a study of 2930 cases, Robert A. Goyer concluded that in- fants, whose umbilical cord blood lead levels were higher than 10 µg/100ml, had sensory, motor, and visual impair- ments, as well as cognitive problems during development (11). Moreover, in a review study, Lisa H. Mason concluded that high levels of lead toxicity in workers cause seizure, lethargy, and coma. In acute cases of lead toxicity, reversible neuropathy occurs (8). In another study, Wilhelm M found that cognitive and be- havioral changes occur at a lead level of 100 µg/100ml; these disorders were more serious in younger patients (12). In our study, long-term lead exposure and high lead level resulted in neuropathy, numbness, and quadriplegia, which gradually resolved with proper chelation therapy. Moreover, in a study on industrial workers Baker EL found that workers with lead levels above 40 µg/100ml experienced problems, such as mood and emotional disorders, exacerbated depression, confusion, anger, and increased tension and fatigue. In the long run, these workers experienced complications, such as memory, cognitive, visual, and verbal impairments (13). In this study, motor problems were not reported. Slight motor problems have been reported in several studies, although quadriplegia and walking disability were not found in the literature; quadriplegia was only reported in some cases. In this study, we reported a patient with a lead level of 150 µg/100ml, associated with quadriplegia and walking disability. 4. Conclusion: Workers who are in contact with industrial lead are exposed to chronic lead toxicity. Delayed detection of serious symp- toms, such as cognitive, sensory, and functional disorders, can be life-threatening for these workers. Therefore, workers exposed to industrial lead are recommended to undergo periodic and regular examinations to prevent any possible complications. 5. Appendix 5.1. Acknowledgements We would like to express our special thanks to the forensic center of Tehran, Iran. 5.2. Author’s contribution All authors meet the four criteria of authorship contribution based on the recommendations of the international commit- tee of medical journal editors. 5.3. Conflict of interest The authors declared no potential conflict of interest. 5.4. Funding None. References 1. Gidlow D. Lead toxicity. Occupational Medicine. 2004;54(2):76-81. 2. Papanikolaou NC, Hatzidaki EG, Belivanis S, Tzanakakis GN, Tsatsakis AM. Lead toxicity update. A brief review. Medical science monitor. 2005;11(10):RA329-RA36. 3. Tandon S, Chatterjee M, Bhargava A, Shukla V, Bihari V. Lead poisoning in Indian silver refiners. Science of the total environment. 2001;281(1-3):177-82. 4. Mason LH, Mathews MJ, Han DY. Neuropsychiatric symptom assessments in toxic exposure. Psychiatric Clinics. 2013;36(2):201-8. 5. Majchrzak M, Celinski R, Kowalska T, Sajewicz M. Fa- tal case of poisoning with a new cathinone derivative: α-propylaminopentiophenone (N-PP). Forensic Toxicol- ogy. 2018:1-9. 6. Rubens O, Logina I, Kravale I, Eglite M, Donaghy M. Peripheral neuropathy in chronic occupational inor- ganic lead exposure: a clinical and electrophysiological study. Journal of Neurology, Neurosurgery & Psychiatry. 2001;71(2):200-4. 7. Wu M-L, Deng J-F, Lin K-P, Tsai W-J. Lead, mercury, and arsenic poisoning due to topical use of traditional Chinese medicines. The American journal of medicine. 2013;126(5):451-4. 8. Mason LH, Harp JP, Han DY. Pb neurotoxicity: neuropsy- chological effects of lead toxicity. BioMed research inter- national. 2014;2014. 9. Baigmohammadi M, Mohammadi M, Mahmoodpour A, Karvandian K, Aghdashi M. Quadriplegia due to lead- contaminated opium&58; a case report. Tehran Univer- sity Medical Journal. 2008;66(7):521-4. 10. Sansar W, Ahboucha S, Gamrani H. Chronic lead in- toxication affects glial and neural systems and in- duces hypoactivity in adult rat. Acta histochemica. 2011;113(6):601-7. 11. Goyer RA. Results of lead research: prenatal exposure and neurological consequences. Environmental Health Per- spectives. 1996;104(10):1050. 12. Wilhelm M, Heinzow B, Angerer J, Schulz C. Reassess- ment of critical lead effects by the German Human Biomonitoring Commission results in suspension of the human biomonitoring values (HBM I and HBM II) for lead in blood of children and adults. Interna- This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: www.jemerg.com M. Mesri et al. 4 tional journal of hygiene and environmental health. 2010;213(4):265-9. 13. Baker EL, Feldman RG, White RF, Harley JP, Dinse GE, Berkey CS. Monitoring neurotoxins in industry: develop- ment of a neurobehavioral test battery. Journal of occu- pational medicine: official publication of the Industrial Medical Association. 1983. This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: www.jemerg.com Introduction Case Presentation: Discussion Conclusion: Appendix References